FBLA Names New Preferred Leadership Partner in Lead4Change

Reston, VA, Nov. 19, 2024 (GLOBE NEWSWIRE) — Lead4Change, a student leadership non-profit committed to empowering educators to develop student leaders, has proudly been named the preferred Leadership Partner of Future Business Leaders of America (FBLA), the nation's largest career and technical student organization. As FBLA's preferred Leadership Partner, Lead4Change will provide students nationwide with […]

Geely Shares Decarbonisation Experience at COP29

— Geely showcase green methanol and circular economy leadership at COP29 — Geely’s green methanol expertise delivers real-world solutions for zero carbon emissions Zhejiang Geely Holding Group (Geely Holding) participated in the 29th United Nations Climate Change Conference (COP29) in Azerbaijan, joining a roundtable forum on reducing carbon emissions within the new energy industry value

Geely Shares Decarbonisation Experience at COP29

— Geely showcase green methanol and circular economy leadership at COP29 — Geely's green methanol expertise delivers real-world solutions for zero carbon emissions Zhejiang Geely Holding Group (Geely Holding) participated in the 29th United Nations Climate Change Conference (COP29) in Azerbaijan, joining a roundtable forum on reducing carbon emissions within the new energy industry value

EasyPR: Transforming Press Release Distribution in the USA with 500+ Media Outlets Coverage Across 30+ Niches

AUSTIN, Texas, Nov. 19, 2024 (GLOBE NEWSWIRE) — EasyPR, a leading premium press release distribution agency, is revolutionizing the way businesses and organizations communicate their news and announcements. With an impressive reach spanning 500+ media outlets, EasyPR has successfully served over 30 niche industries, solidifying its position as a trusted partner for impactful press release

EasyPR: Transforming Press Release Distribution in the USA with 500+ Media Outlets Coverage Across 30+ Niches

AUSTIN, Texas, Nov. 19, 2024 (GLOBE NEWSWIRE) — EasyPR, a leading premium press release distribution agency, is revolutionizing the way businesses and organizations communicate their news and announcements. With an impressive reach spanning 500+ media outlets, EasyPR has successfully served over 30 niche industries, solidifying its position as a trusted partner for impactful press release

OpusVi and CommonSpirit Health Achieve 92% New Nurse Retention, Saving $16M Annually With System-Wide Nurse Residency & Preceptor Training

OpusVi and CommonSpirit Health join forces to support new nursing graduates through a system-wide Nurse Residency, Preceptor and Mentor Program. Streamlined, standardized training aims to reverse the trend of high turnover rates among new nurses and mounting recruitment and hiring costs across the 24-state system. OpusVi™ (formerly Dignity Health Global Education), a leading workforce development

OpusVi and CommonSpirit Health Achieve 92% New Nurse Retention, Saving $16M Annually With System-Wide Nurse Residency & Preceptor Training

OpusVi and CommonSpirit Health join forces to support new nursing graduates through a system-wide Nurse Residency, Preceptor and Mentor Program. Streamlined, standardized training aims to reverse the trend of high turnover rates among new nurses and mounting recruitment and hiring costs across the 24-state system. OpusVi™ (formerly Dignity Health Global Education), a leading workforce development

Concerto Biosciences Announces First Participant Dosed with Live Biotherapeutic ENS-002 in Phase 1 Trial for Atopic Dermatitis

ENS-002 leverages a carefully selected trio of microbes to subdue virulent, inflammation-causing S. aureus, a core microbial driver of atopic dermatitis, offering a potential novel avenue for treatment. Concerto Biosciences, a biotechnology company that leverages a powerful screening technology called kChip to rapidly discover microbial, prebiotic, and postbiotic product candidates, today announced the first participant

Concerto Biosciences Announces First Participant Dosed with Live Biotherapeutic ENS-002 in Phase 1 Trial for Atopic Dermatitis

ENS-002 leverages a carefully selected trio of microbes to subdue virulent, inflammation-causing S. aureus, a core microbial driver of atopic dermatitis, offering a potential novel avenue for treatment. Concerto Biosciences, a biotechnology company that leverages a powerful screening technology called kChip to rapidly discover microbial, prebiotic, and postbiotic product candidates, today announced the first participant

ABK Biomedical Announces FDA IDE Stage 2 Approval for Route90, a Prospective, Multi-Center, Pivotal Study of Eye90 microspheres® in unresectable Hepatocellular Cancer

ABK Biomedical, Inc., an innovative, medical device company dedicated to the research, development, and commercialization of advanced imageableembolic medical devices, has received FDA approval to advance its Investigational Drug Exemption (IDE) study into its pre-planned, Stage 2 enrollment cycle. This FDA approval is based upon their review and assessment of interim safety outcomes from the

Scroll to Top